There is tremendous potential to impact the burden of risk factors for heart disease, particularly hypertension in India. Carvedilol will provide physicians an effective option to manage patients wit
India, Republic of (Press Release) August 29, 2007 --
GlaxoSmithKline Pharmaceuticals Limited has entered the cardiovascular segment in India with Carvedilol, a beta-blocker for the management of hypertension under the brand name ‘Carzec’. GSK markets this drug in the US under the name Coreg, a blockbuster brand worth over US$ 1 billion (over Rs.4000 crores).
Hypertension or high blood pressure is a serious issue in India and has steadily increased from 5% in the 1960s to 12 – 15% in the 1990s. High blood pressure or hypertension is directly associated with risks of several types of cardiovascular disease but can be controlled conveniently and effectively. Carzec (Carvedilol) acts by reducing the workload on the heart, thus reducing blood pressure. In addition, it has anti-oxidant and cardioprotective properties and is glucose and lipid friendly.
Hypertension or high blood pressure is a serious issue in India and has steadily increased from 5% in the 1960s to 12 – 15% in the 1990s. High blood pressure or hypertension is directly associated with risks of several types of cardiovascular disease but can be controlled conveniently and effectively. Carzec (Carvedilol) acts by reducing the workload on the heart, thus reducing blood pressure. In addition, it has anti-oxidant and cardioprotective properties and is glucose and lipid friendly.
Email
Print
SPAM
